Elacestrant in Advanced Triple Positive Breast Cancer

The purpose of this study to assess the safety and efficacy of elacestrant, a selective estrogen receptor degrader (SERD) and dual biologic therapy, trastuzumab and pertuzumab, in patients with triple-positive breast cancer with and without an ESR1 mutation.

Trial Details

NCT ID
NCT07612215
Phase
PHASE1 / PHASE2
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Elacestrant
  • Trastuzumab
  • Pertuzumab
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Female patients aged 18 years or older.
  • Should be able to provide the informed consent.
  • Histologically confirmed diagnosis of triple-positive breast cancer (ER+, PR+, HER2+). In the study, ER status will be considered positive if ≥10% …
  • Disease progression on or after at least one line of NCCN recommended prior therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →